New Era Capital Partners
New Era Capital Partners is a venture capital firm established in 2018 and based in Tel Aviv, Israel. The firm focuses on early-stage investments in technology companies that align with environmental, social, and governance (ESG) principles. It primarily targets sectors such as information technology, fintech, software as a service (SaaS), digital health, agricultural technology, and telecommunications and media technology (TMT). New Era Capital Partners aims to invest in 12 to 14 companies, emphasizing the importance of impact investing alongside financial returns.
Variantyx Inc. is a biotechnology company based in Framingham, Massachusetts, founded in 2014. The company specializes in diagnostic testing for rare disorders through its whole genome sequencing (WGS) platform, known as Genomic Unity®. This innovative test analyzes a single patient sample to identify and report all major variant types, including small sequence changes, structural variants, mitochondrial variants, and short tandem repeat expansions. By providing a comprehensive approach to genetic testing, Variantyx eliminates the need for traditional, step-wise genetic testing methods. The platform is designed to generate clinical reports that help hospitals and commercial laboratories accurately understand a patient's genetic makeup, leading to improved diagnosis and optimized treatment recommendations for inherited disorders.
Variantyx Inc. is a biotechnology company based in Framingham, Massachusetts, founded in 2014. The company specializes in diagnostic testing for rare disorders through its whole genome sequencing (WGS) platform, known as Genomic Unity®. This innovative test analyzes a single patient sample to identify and report all major variant types, including small sequence changes, structural variants, mitochondrial variants, and short tandem repeat expansions. By providing a comprehensive approach to genetic testing, Variantyx eliminates the need for traditional, step-wise genetic testing methods. The platform is designed to generate clinical reports that help hospitals and commercial laboratories accurately understand a patient's genetic makeup, leading to improved diagnosis and optimized treatment recommendations for inherited disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.